Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid

Mutation Research - Reviews in Mutation Research

Volumn 753, Issue 1, 2013, Pages 41-49

  Hollstein, M ^a,b   Moriya, M ^c   Grollman, A P ^c   Olivier, M ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c STONY BROOK UNIVERSITY   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Aristolochic acid(s); Herbal remedies; Hotspot mutations; Nephropathy; TP53 mutation; Urothelial cancer

Indexed keywords

ARISTOLOCHIC ACID; CARCINOGEN; PROTEIN P53;

ARISTOLOCHIA; CHRONIC KIDNEY DISEASE; DNA FINGERPRINTING; EXPOSURE; GENE FREQUENCY; GENE MUTATION; LABORATORY TEST; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; URINARY TRACT;

7-(DEOXYADENOSIN-N(6)-YL)ARISTOLACTAM; AA; AA-UUT; AL-DA; AL-DNA ADDUCTS; ARISTOLACTAM-DNA ADDUCTS; ARISTOLOCHIC ACID(S); BALKAN ENDEMIC NEPHROPATHY; BEN; CATALOGUE OF SOMATIC MUTATIONS IN CANCER; COSMIC; HERBAL REMEDIES; HOTSPOT MUTATIONS; HUF; HUPKI EMBRYONIC FIBROBLASTS; IARC; IARC DB; IARC TP53 DATABASE; ICGC; INTERNATIONAL AGENCY FOR RESEARCH ON CANCER; INTERNATIONAL CANCER GENOME CONSORTIUM; LOF; LOSS OF WILD-TYPE FUNCTION; NEPHROPATHY; NONAA-UUT; THE HUMAN P53 TUMOR SUPPRESSOR GENE; THE MOUSE P53 TUMOR SUPPRESSOR GENE; TP53; TP53 MUTATION; TRP53; UPPER URINARY TRACT TUMORS; UROTHELIAL CANCER; UUT; UUT TUMORS FROM PATIENT COHORTS WITH DOCUMENTED OR SUSPECTED EXPOSURE TO AA; UUT TUMORS FROM PATIENT COHORTS WITH NO KNOWN OR SUSPECTED EXPOSURE TO AA;

ANIMALS; ARISTOLOCHIC ACIDS; BALKAN NEPHROPATHY; CARCINOGENS; HUMANS; MICE; MUTATION; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS;

ARISTOLOCHIA CLEMATITIS; TRITICUM AESTIVUM;

EID: 84881252776     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2013.02.003     Document Type: Review

References (57)

1. Vogelstein B., Kinzler K.W. Carcinogens leave fingerprints. Nature 1992, 355:209-210.
2. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
3. Giglia-Mari G., Sarasin A. TP53 mutations in human skin cancers. Hum. Mutat. 2003, 21:217-228.
4. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
5. Pfeifer G.P., Hainaut P. On the origin of G --> T transversions in lung cancer. Mutat. Res. 2003, 526:39-43.
6. DeMarini D.M., Landi S., Tian D., Hanley N.M., Li X., Hu F., Roop B.C., Mass M.J., Keohavong P., Gao W., Olivier M., Hainaut P., Mumford J.L. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Res. 2001, 61:6679-6681.
7. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
8. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., Lin M.L., Beare D., Lau K.W., Greenman C., Varela I., Nik-Zainal S., Davies H.R., Ordonez G.R., Mudie L.J., Latimer C., Edkins S., Stebbings L., Chen L., Jia M., Leroy C., Marshall J., Menzies A., Butler A., Teague J.W., Mangion J., Sun Y.A., McLaughlin S.F., Peckham H.E., Tsung E.F., Costa G.L., Lee C.C., Minna J.D., Gazdar A., Birney E., Rhodes M.D., McKernan K.J., Stratton M.R., Futreal P.A., Campbell P.J. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
9. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M.L., Ordonez G.R., Bignell G.R., Ye K., Alipaz J., Bauer M.J., Beare D., Butler A., Carter R.J., Chen L., Cox A.J., Edkins S., Kokko-Gonzales P.I., Gormley N.A., Grocock R.J., Haudenschild C.D., Hims M.M., James T., Jia M., Kingsbury Z., Leroy C., Marshall J., Menzies A., Mudie L.J., Ning Z., Royce T., Schulz-Trieglaff O.B., Spiridou A., Stebbings L.A., Szajkowski L., Teague J., Williamson D., Chin L., Ross M.T., Campbell P.J., Bentley D.R., Futreal P.A., Stratton M.R. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
10. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
11. Besaratinia A., Pfeifer G.P. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J. 2010, 24:2612-2619.
12. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001, 20:320-328.
13. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
14. Petronic V. Tumors of the upper urothelium and endemic nephropathy. Endemic Nephropathy 2000, 350-439. Institute for Textbook Publishing, Belgrade, Serbia. Z. Radovanovic, M. Sindic, M. Polenakovic, L. Djukanovic, V. Petronic (Eds.).
15. Lai M.N., Wang S.M., Chen P.C., Chen Y.Y., Wang J.D. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl. Cancer Inst. 2010, 102:179-186.
16. Yang M.H., Chen K.K., Yen C.C., Wang W.S., Chang Y.H., Huang W.J., Fan F.S., Chiou T.J., Liu J.H., Chen P.M. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002, 59:681-687.
17. Chen C.H., Dickman K.G., Moriya M., Zavadil J., Sidorenko V.S., Edwards K.L., Gnatenko D.V., Wu L., Turesky R.J., Wu X.R., Pu Y.S., Grollman A.P. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8241-8246.
18. Grollman A.P. Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ. Mol. Mutagen. 2013, 54:1-7.
19. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelic M., Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12129-12134.
20. Jelakovic B., Karanovic S., Vukovic-Lela I., Miller F., Edwards K.L., Nikolic J., Tomic K., Slade N., Brdar B., Turesky R.J., Stipancic Z., Dittrich D., Grollman A.P., Dickman K.G. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012, 81:559-567.
21. Moriya M., Slade N., Brdar B., Medverec Z., Tomic K., Jelakovic B., Wu L., Truong S., Fernandes A., Grollman A.P. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 2011, 129:1532-1536.
22. Arlt V.M., Stiborova M., vom B.J., Simoes M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., Schmeiser H.H. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007, 28:2253-2261.
23. De Broe M.E. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity aristolochic acid nephropathy. Kidney Int. 2012, 81:513-515.
24. Grollman A.P., Scarborough J., Jelakovic B. Aristolochic acid nephropathy: an environmental and iatrogenic disease. Adv. Mol. Tox. 2009, 3:211-227.
25. Olivier M., Hollstein M., Schmeiser H.H., Straif K., Wild C.P. Upper urinary tract urothelial cancers: where it is A:T. Nat. Rev. Cancer 2012, 12:503-504.
26. Schetter A.J., Harris C.C. Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7955-7956.
27. Djukanovic L., Radovanovic Z. Balkan endemic nephropathy. Clinical Nephrotoxins 2003, 588-601. Kluwer, Dordrecht. M. De Broe, G. Porter, W. Bennett, G. Verppoten (Eds.).
28. Shibutani S., Dong H., Suzuki N., Ueda S., Miller F., Grollman A.P. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 2007, 35:1217-1222.
29. Hsieh S.C., Lin I.H., Tseng W.L., Lee C.H., Wang J.D. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med. 2008, 3:13.
30. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De P.L., Abramowicz D., Vereerstraeten P., Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000, 342:1686-1692.
31. Mengs U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch. Toxicol. 1983, 52:209-220.
32. Mengs U. Tumour induction in mice following exposure to aristolochic acid. Arch. Toxicol. 1988, 61:504-505.
33. Sidorenko V.S., Yeo J.E., Bonala R.R., Johnson F., Scharer O.D., Grollman A.P. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 2012, 40:2494-3505.
34. Martinez M.C., Nortier J., Vereerstraeten P., Vanherweghem J.L. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol. Dial. Transplant. 2002, 17:408-412.
35. Lai M.N., Lai J.N., Chen P.C., Hsieh S.C., Hu F.C., Wang J.D. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am. J. Kidney Dis. 2010, 55:507-518.
36. Grollman A.P., Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia. J Am. Soc. Nephrol. 2007, 18:2817-2823.
37. Hranjec T., Kovac A., Kos J., Mao W., Chen J.J., Grollman A.P., Jelakovic B. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat. Med. J. 2005, 46:116-125.
38. Ivic M. Etiology of endemic nephropathy. Lijec. Vjesn. 1969, 91:1273-1281.
39. Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 2004, 43:e11-e17.
40. Sidorenko V.S., Yeo J.E., Bonala R.R., Johnson F., Scharer O.D., Grollman A.P. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 2012, 40:2494-2505.
41. Attaluri S., Bonala R.R., Yang I.Y., Lukin M.A., Wen Y., Grollman A.P., Moriya M., Iden C.R., Johnson F. DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 2010, 38:339-352.
42. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8424-8429.
43. Marcel V., Hainaut P. p53 isoforms - a conspiracy to kidnap p53 tumor suppressor activity?. Cell. Mol. Life Sci. 2009, 66:391-406.
44. Wang Y., Arlt V.M., Roufosse C.A., McKim K.L., Myers M.B., Phillips D.H., Parsons B.L. ACB-PCR measurement of H-ras codon 61 CAA-->CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. Environ. Mol. Mutagen. 2012, 53:495-504.
45. McDaniel L.P., Elander E.R., Guo X., Chen T., Arlt V.M., Mei N. Mutagenicity and DNA adduct formation by aristolochic acid in the spleen of Big Blue(R) rats. Environ. Mol. Mutagen. 2012, 53:358-368.
46. Xing G., Qi X., Chen M., Wu Y., Yao J., Gong L., Nohmi T., Luan Y., Ren J. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney. Mutat. Res. 2012, 743:52-58.
47. Hergenhahn M., Luo J.L., Hollstein M. p53 designer genes for the modern mouse. Cell Cycle 2004, 3:738-741.
48. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2963-2968.
49. vom Brocke J., Schmeiser H.H., Reinbold M., Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 2006, 27:2141-2147.
50. Nedelko T., Arlt V.M., Phillips D.H., Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer 2009, 124:987-990.
51. Reinbold M., Luo J.L., Nedelko T., Jerchow B., Murphy M.E., Whibley C., Wei Q., Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008, 27:2788-2794.
52. Whibley C., Odell A.F., Nedelko T., Balaburski G., Murphy M., Liu Z., Stevens L., Walker J.H., Routledge M., Hollstein M. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J. Biol. Chem. 2010, 285:11326-11335.
53. Hollstein M., Marion M.J., Lehman T., Welsh J., Harris C.C., Martel-Planche G., Kusters I., Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride- exposed factory workers. Carcinogenesis 1994, 15:1-3.
54. Weihrauch M., Lehnert G., Kockerling F., Wittekind C., Tannapfel A. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 2000, 88:1030-1036.
55. Rothberg J.M., Hinz W., Rearick T.M., Schultz J., Mileski W., Davey M., Leamon J.H., Johnson K., Milgrew M.J., Edwards M., Hoon J., Simons J.F., Marran D., Myers J.W., Davidson J.F., Branting A., Nobile J.R., Puc B.P., Light D., Clark T.A., Huber M., Branciforte J.T., Stoner I.B., Cawley S.E., Lyons M., Fu Y., Homer N., Sedova M., Miao X., Reed B., Sabina J., Feierstein E., Schorn M., Alanjary M., Dimalanta E., Dressman D., Kasinskas R., Sokolsky T., Fidanza J.A., Namsaraev E., McKernan K.J., Williams A., Roth G.T., Bustillo J. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475:348-352.
56. Rosenquist T.A. Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse. Am. J. Physiol. Renal Physiol. 2011, 300:F1360-F1367.
57. Stiborova M., Frei E., Arlt V.M., Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 2008, 658:55-67.